RIZZUTO MARIA ANTONIETTA

Ruolo: 
assegnista di ricerca

Didattica

A.A.: 2016/2017

A.A.: 2015/2016

Pubblicazioni

  • Riva, B., Bellini, M., Corvi, E., Verderio, P., Rozek, E., Colzani, B., et al. (2018). Impact of the strategy adopted for drug loading in nonporous silica nanoparticles on the drug release and cytotoxic activity. JOURNAL OF COLLOID AND INTERFACE SCIENCE, 519, 18-26. Dettaglio
  • Colombo, M., Rizzuto, M., Pacini, C., Pandolfi, L., Bonizzi, A., Truffi, M., et al. (2018). Half-Chain Cetuximab Nanoconjugates Allow Multitarget Therapy of Triple Negative Breast Cancer. BIOCONJUGATE CHEMISTRY, 29(11), 3817-3832. Dettaglio
  • Mazzucchelli, S., Truffi, M., Baccarini, F., Beretta, M., Sorrentino, L., Bellini, M., et al. (2017). H-Ferritin-nanocaged olaparib: A promising choice for both BRCA-mutated and sporadic triple negative breast cancer. SCIENTIFIC REPORTS, 7(1). Dettaglio
  • Pandolfi, L., Bellini, M., Vanna, R., Morasso, C., Zago, A., Carcano, S., et al. (2017). H-Ferritin Enriches the Curcumin Uptake and Improves the Therapeutic Efficacy in Triple Negative Breast Cancer Cells. BIOMACROMOLECULES, 18(10), 3318-3330. Dettaglio
  • Mazzucchelli, S., Bellini, M., Fiandra, L., Truffi, M., Rizzuto, M., Sorrentino, L., et al. (2017). Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity. ONCOTARGET, 8(5), 8383-8396. Dettaglio